Drug Profile
Research programme: cancer therapeutics - Synlogic/Phio Pharmaceuticals
Alternative Names: RNAi-based cancer therapies - Synlogic/Phio PharmaceuticalsLatest Information Update: 21 Nov 2018
Price :
$50
*
At a glance
- Originator Mirna Therapeutics; RXi Pharmaceuticals Corporation
- Developer Galena Biopharma; Mirna Therapeutics
- Class Small interfering RNA; Small molecules
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Liver cancer